Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma

Abstract

It is a golden age for cancer drug development. There are frequent announcements of regulatory approvals of new drugs, or more commonly, an existing but fairly new drug or drug combination for yet another indication. Immune checkpoint inhibitors and antibody drug conjugates are among the most common of such recent approvals. One disadvantage of this otherwise remarkable development is the enormous cost of such drugs, thereby placing an ever increasing financial burden on health-care systems and making it virtually impossible for most patients with cancer, especially those who live in low-income and middle-income countries (LMICs), to benefit from these successes.